{"id":"60494614-5852-54c8-a30c-0436166ee069","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-hud-binding","predicate":"reported_relationship","statement":"The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"a81dbaf5-08da-57c4-9ef3-785e75b9a56c","mechanism_event_label":"The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"a2b44eff-5bb0-50b1-aa25-00038cd94d09","slug":"human-elavl4","display_name":"Human ELAVL4 / HuD RNA-binding protein","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"a81dbaf5-08da-57c4-9ef3-785e75b9a56c","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-hud-binding-event","event_type":"experimental_observation","label":"The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.","description":"### ra-hud-binding\n\nThe HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.\nBinding is not functional inhibition. Folic-acid follow-up cell results are not RA results; RA clinical neuronal benefit remains untested.\nModel and exposure: Virtual screening followed by STD-NMR; authors identify four hits.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. | 2021 | https://pubmed.ncbi.nlm.nih.gov/34219450/ | https://doi.org/10.1021/acs.jmedchem.1c00191 | Access: Indexed primary abstract only; author follow-up identifies RA among prior binding hits. Full 2021 text unavailable.\nReference: Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid? | 2023 | https://pubmed.ncbi.nlm.nih.gov/37569576/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10418318/ | https://doi.org/10.3390/ijms241512201 | Access: Primary author follow-up Introduction passages describing the previous HuD binding study; new folic-acid cell findings are not RA findings.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"a2b44eff-5bb0-50b1-aa25-00038cd94d09","slug":"human-elavl4","display_name":"Human ELAVL4 / HuD RNA-binding protein","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract only; author follow-up identifies RA among prior binding hits. Full 2021 text unavailable.; Primary author follow-up Introduction passages describing the previous HuD binding study; new folic-acid cell findings are not RA findings.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Virtual screening followed by STD-NMR; authors identify four hits.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. | https://pubmed.ncbi.nlm.nih.gov/34219450/ | https://doi.org/10.1021/acs.jmedchem.1c00191","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid? | https://pubmed.ncbi.nlm.nih.gov/37569576/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10418318/ | https://doi.org/10.3390/ijms241512201","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-hud-binding; Binding is not functional inhibition. Folic-acid follow-up cell results are not RA results; RA clinical neuronal benefit remains untested.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"018ba3cf-7058-5fd8-9adb-a4d7ad532df7","evidence_kind":"source_excerpt","locator":"Lines 481-488","start_line":481,"end_line":488,"excerpt":"### ra-hud-binding\n\nThe HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.\nBinding is not functional inhibition. Folic-acid follow-up cell results are not RA results; RA clinical neuronal benefit remains untested.\nModel and exposure: Virtual screening followed by STD-NMR; authors identify four hits.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. | 2021 | https://pubmed.ncbi.nlm.nih.gov/34219450/ | https://doi.org/10.1021/acs.jmedchem.1c00191 | Access: Indexed primary abstract only; author follow-up identifies RA among prior binding hits. Full 2021 text unavailable.\nReference: Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid? | 2023 | https://pubmed.ncbi.nlm.nih.gov/37569576/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10418318/ | https://doi.org/10.3390/ijms241512201 | Access: Primary author follow-up Introduction passages describing the previous HuD binding study; new folic-acid cell findings are not RA findings.","model_system":"Virtual screening followed by STD-NMR; authors identify four hits.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}